Researchers at Umeå University have developed a new class of synthetic antibiotic compounds called TriPcides. These compounds target the bacterium Staphylococcus aureus, including antibiotic-resistant strains such as Methicillin-resistant Staphylococcus aureus (MRSA), and have demonstrated activity against dormant persister cells.
Mechanism and Efficacy
The TriPcides function by disrupting bacterial cell membranes and interfering with processes essential for establishing infection. In laboratory studies, the compounds were active against several types of Gram-positive bacteria, including resistant strains.
A key feature of the compounds is their effectiveness against persister cells—bacteria that exist in a dormant, metabolically inactive state. According to the researchers, these cells can survive treatment with conventional antibiotics and resume growth after treatment ends, potentially causing infection relapse.
Resistance Profile
In laboratory studies, no existing resistance to TriPcides was observed across a range of clinical bacterial isolates. The researchers also reported that the bacteria studied did not easily develop resistance to these synthetic compounds.
"We have developed an entirely new class of compounds with very promising antibacterial properties. What stands out is that the bacteria we have studied do not easily develop resistance to these synthetic antibiotics. We have also not observed any existing resistance in a wide range of clinical isolates, which is encouraging."
— Fredrik Almqvist, Professor, Department of Chemistry, Umeå University
Regarding persister cells, Almqvist said: "Persister cells are bacteria that enter a state similar to dormancy, in which they do not divide and are metabolically inactive. A small fraction of the bacteria causing an infection are in this state and can therefore survive antibiotic treatment. Once treatment ends, they can resume growth and cause the infection to return. Our TriPcides also showed activity against persister cells, which is very exciting."
Almqvist added: "This study is the first to investigate this new type of antibiotic and offers hope that we can continue developing effective new treatments. There is a significant global need for new types of antibiotics to which bacteria have not already developed resistance, and this discovery is a positive step forward."
Context and Next Steps
Antibiotic resistance is considered a growing global health concern, increasing the risk of difficult-to-treat infections, longer hospital stays, and higher mortality rates. The researchers indicate that TriPcides could contribute to new treatment approaches for severe infections, but note that further research is required before the compounds can be applied clinically.
The study was an international collaboration involving three research groups at Umeå University and the Umeå Centre for Microbial Research (UCMR).